60 likes | 181 Views
Global Health Conference, Brussels, June 10-11, 2010. Overcoming barriers to innovation and ensuring access. Session C - Innovation and Access François Bompart, MD Sanofi Aventis - EFPIA. Access to healthcare (1). High percentage of global populations lacks adequate access to healthcare
E N D
Global Health Conference,Brussels, June 10-11, 2010 Overcoming barriers to innovation and ensuring access Session C - Innovation and Access François Bompart, MD Sanofi Aventis - EFPIA
Access to healthcare (1) • High percentage of global populations lacks adequate access to healthcare • Does not exist • Too expensive • Too remote • Too difficult to deliver with existing infrastructure • Substandard • Healthcare deficiencies do not exist in isolation • Basic infrastructure (water, roads) • Insufficient Government budgets • Underdeveloped Healthcare financing systems • Lack of technical/scientific capacity
Access to healthcare (2) • « Access to healthcare » broader issue than « Access to medicines » • Political will to invest in heathcare • Human resources & infrastructures • Insurance systems, public and private • Availability of prevention interventions • Sanitation, access to safe water and food, health information... • Access to medicines and other commodities • « Access to medicines » broader issue than « Price of medicines » • Drugs adapted to patients’ and health professionals’ needs • Availability of diagnostic methods • Information of healthcare providers, communities and patients • Efficiency of distribution systems • Drugs only go to places where someone orders them • Price of medicines and other commodities
Innovation • Investments in innovation conditionned by science and market potential 1. Scientific lead + Potential market • Program included in « mainstream » pharmaceutical R&D 2. NO Scientific lead yet, but potential market • Research performed: academic and pharmaceutical 3. Scientific lead + NO Potential market • New economic model needed to include program in pharmaceutical R&D (Public-Private partnerships, incentive programs, etc.) • In pharmaceuticals, major innovations take >> 10 years to reach patients • Do not underestimate « small » innovations (e.g. antimalarial fixed-dose combinations, pediatric formulations, etc.)
Poverty and lack of access to healthform a vicious circle • What will transform the vicious circle? • Economic growth • Domestic advocacy for better healthcare • Innovative approaches to financing • Improved access to healthcare • Research & Development for neglected diseases and patients • Focused and sustainable actions on specific health threats and horizontal programmes • Collective action through partnerships which bridge the developed and developing world
What can the EU do ? • Promote idea of equity in access to health worldwide • Solidarity chain • Foster investment in healthcare by • Supporting the enabling conditions in developing countries • Seed funding for scientific infrastructure • Encourage development of partnerships • Promote efficient regulatory approaches • Help developing countries effectively control their own environment (e.g. quality of medicines) • Provide « even field » for innovators and investors • Develop incentives for innovation in neglected diseases and neglected patients • Including “small” innovations with quick impact • Chronic diseases as well as transmissible diseases